Implantable Cardioverter Defibrillator Versus Optimal Medical Therapy In Patients With Variant Angina Manifesting as Aborted Sudden Cardiac Death

  • End date
    Jun 24, 2023
  • participants needed
  • sponsor
    Kee-joon Choi
Updated on 24 January 2021


The purpose of this study is to determine whether ICD(Implantable Cardioverter Defibrillator) implantation on the top of optimal medical therapy in patients with variant angina manifesting as aborted sudden cardiac death reduces the incidence of the death from any cause compared with optimal medical therapy alone.

Condition Sudden Cardiac Death, Prinzmetal Angina
Treatment Implantable Cardioverter Defibrillator, Optimal medical therapy
Clinical Study IdentifierNCT02845531
SponsorKee-joon Choi
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Age 18 years or older
Patients experienced successfully resuscitated cardiac arrest due to documented ventricular fibrillation or sustained rapid ventricular tachycardia
Diagnosed as variant angina, defined by spontaneous coronary spasm with ST elevation (0.1mV) in the coronary angiogram and/or documented coronary spasm on ergonovine provocation coronary angiography

Exclusion Criteria

Significant (>50%) coronary artery stenosis on coronary angiography
Organic heart disease known to be associated with sudden cardiac arrest
Heart failure with reduced ejection fraction (Left Ventricular Ejection Fraction < 35%)
Presence of LV akinesia or aneurysm
Hypertrophic cardiomyopathy
Arrhythmogenic right ventricular dysplasia
Chronic Heart Failure New York Heart Association functional class III or IV
prior history of atrial or ventricular arrhythmia requiring class I or III antiarrhythmic drugs (flecainide, propafenone, amiodarone, sotalol and dronedarone)
Prior catheter ablation for ventricular arrhythmia
Primary cardiac electrical diseases (long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia)
Prior pacemaker or Implantable Cardioverter Defibrillator
nd or 3rd degree AV block not related to coronary ischemia, requiring permanent pacemaker
Patients with poor neurologic outcome (defined as cerebral performance category scale 3)
Life expectancy <2 years
Psychiatric illnesses that may be aggravated by device implantation or that may preclude systematic follow-up
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note